Stock TARSUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tarsus Pharmaceuticals, Inc. Nasdaq

Equities

US87650L1035

Pharmaceuticals

End-of-day quote Nasdaq
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Tarsus Pharmaceuticals, Inc. -.--% -.--%
06-10 Transcript : Tarsus Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:00 PM
05-31 Certain Restricted Stock Units of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024. CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 839.8 465.2 391 670.4 1,041 - -
Enterprise Value (EV) 1 839.8 465.2 391 472.1 899 926.2 818
P/E ratio -9.57 x -33.6 x -5.82 x -4.38 x -7.27 x -20.3 x 10.8 x
Yield - - - - - - -
Capitalization / Revenue - 8.16 x 15.1 x 38.4 x 7.16 x 3.86 x 2.36 x
EV / Revenue - 8.16 x 15.1 x 27.1 x 6.19 x 3.44 x 1.86 x
EV / EBITDA -31.2 x -39.3 x -6.27 x -3.32 x -6.15 x -13.2 x 29 x
EV / FCF -38,892,433 x 147,132,296 x - - - - -
FCF Yield -0% 0% - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 20,320 20,677 26,672 33,105 37,782 - -
Reference price 2 41.33 22.50 14.66 20.25 27.55 27.55 27.55
Announcement Date 21-03-31 22-03-14 23-03-13 24-02-27 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 57.03 25.82 17.45 145.3 269.6 440.6
EBITDA 1 -26.9 -11.84 -62.39 -142.3 -146.3 -70.38 28.16
EBIT 1 -27 -12.16 -62.71 -143.2 -144.6 -63.52 70.6
Operating Margin - -21.32% -242.92% -820.53% -99.51% -23.56% 16.02%
Earnings before Tax (EBT) 1 -26.81 -13.77 -62.1 -135.9 -142.2 -51.06 115.9
Net income 1 -26.81 -13.83 -62.09 -135.9 -139.7 -51.06 115.5
Net margin - -24.25% -240.51% -778.89% -96.14% -18.94% 26.2%
EPS 2 -4.320 -0.6700 -2.520 -4.620 -3.787 -1.358 2.557
Free Cash Flow -21.59 3.162 - - - - -
FCF margin - 5.54% - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 21-03-31 22-03-14 23-03-13 24-02-27 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 0.338 0.539 15.28 - 10 2.5 - 1.871 13.08 27.61 32.38 39.18 46.07 52.2 62
EBITDA 1 -14.41 -19.48 -5.132 -22.81 -14.96 -24.85 -32.64 - -44.1 - -32.75 -26.48 - - -
EBIT 1 -14.45 -19.52 -5.224 -22.91 -15.06 -24.95 -32.82 -40.94 -44.45 -37.68 -36.22 -35.34 -35.3 - -
Operating Margin -4,274.56% -3,621.71% -34.2% - -150.61% -998.08% - -2,187.87% -339.94% -136.47% -111.88% -90.2% -76.63% - -
Earnings before Tax (EBT) 1 -14.8 -20.24 -5.743 -22.52 -13.6 -23.42 -31.42 -39.15 -41.9 -35.73 -36.15 -37 -35.78 - -
Net income 1 -14.85 -20.24 -5.743 -22.51 -13.6 -23.42 -31.42 -39.15 -41.9 -35.73 -34.78 -33.49 -33.63 - -
Net margin -4,393.79% -3,754.73% -37.59% - -135.99% -936.76% - -2,092.36% -320.45% -129.39% -107.43% -85.46% -73% - -
EPS 2 -0.7200 -0.9800 -0.2400 -0.8400 -0.4900 -0.8800 -1.170 -1.280 -1.310 -1.010 -0.9643 -0.9129 -0.9043 -0.9600 -0.6700
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 22-03-14 22-05-10 22-08-11 22-11-09 23-03-13 23-05-09 23-08-10 23-11-09 24-02-27 24-05-08 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - - - 198 142 115 223
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow -21.6 3.16 - - - - -
ROE (net income / shareholders' equity) -33.5% -8.31% -34.5% -69.7% -95.9% - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share 2 -3.410 0.1800 -1.990 -4.000 -3.290 -1.150 -
Capex 0.46 0.59 0.51 - - - -
Capex / Sales - 1.03% 1.96% - - - -
Announcement Date 21-03-31 22-03-14 23-03-13 24-02-27 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Tarsus Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
28.24 USD
Average target price
56.89 USD
Spread / Average Target
+101.45%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.55% 823B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+42.31% 641B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.83% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.15% 324B
ABBVIE INC. Stock AbbVie Inc.
+7.09% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.02% 241B
ROCHE HOLDING AG Stock Roche Holding AG
+1.64% 223B
NOVARTIS AG Stock Novartis AG
+13.66% 218B
AMGEN INC. Stock Amgen Inc.
+7.87% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TARS Stock
  4. Stock
  5. Financials Tarsus Pharmaceuticals, Inc.